SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine

Toxicology and Applied Pharmacology

Volumn 262, Issue 3, 2012, Pages 293-300

  Zhao, Cuirong ^a   Yue, Bin ^a   Liu, Huiping ^a   Sun, Cuicui ^a   Li, Wenbao ^b   Qu, Xianjun ^a  

^a SHANDONG UNIVERSITY   (China)

^b Sanlugen PharmaTech   (China)

Author keywords

Apoptosis; Colon cancer; Gemcitabine; Inhibitory effect; Non small cell lung cancer; Oral derivative

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; GEMCITABINE; PHOSPHATIDYLSERINE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BAX; PROTEIN BCL 2; SL 01; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN HCT116; CHROMATIN CONDENSATION; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NICK END LABELING; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DEOXYCYTIDINE; ENZYME ACTIVATION; FEMALE; HUMANS; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION;

MUS MUSCULUS;

EID: 84863846102     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.05.006     Document Type: Article

References (27)

1. Bender D.M., Bao J., Dantzig A.H., Diseroad W.D., Law K.L., Magnus N.A., Peterson J.A., Perkins E.J., Pu Y.J., Reutzel-Edens S.M., Remick D.M., Starling J.J., Stephenson G.A., Vaid R.K., Zhang D., McCarthy J.R. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J. Med. Chem. 2009, 52:6958-6961.
2. Catt L., Airoldi M., Delprino L., Passera R., Milla P., Pedani F. Pharmacokinetic evaluation of gemcitabine and 2',2'-difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann. Oncol. 2006, 5:142-147.
3. Cui S.X., Qu X.J., Gao Z.H., Zhang Y.S., Zhang X.F., Zhao C.R., Xu W.F., Li Q.B., Han J.X. Targeting aminopeptidase N (APN/CD13) with cyclic-imide peptidomimetics derivative CIP-13F inhibits the growth of human ovarian carcinoma cells. Cancer Lett. 2010, 292:153-162.
4. Gandhi V., Plunkett W. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 1990, 50:3675-3680.
5. Gmeiner W.H., Yu S., Pon R.T., Pourquier P., Pommier Y. Structural basis for topoisomerase I inhibition by nucleoside analogs. Nucleosides Nucleotides Nucleic Acids 2003, 22:653-658.
6. Guan F., Zhang D., Wang X., Chen J. Nitric oxide and bcl-2 mediated the apoptosis induced by nickel(II) in human T hybridoma cells. Toxicol. Appl. Pharmacol. 2007, 221:86-94.
7. Guchelaar H.J., Richel D.J., van Knapen A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat. Rev. 1996, 22:15-31.
8. Hertel L.W., Kroin J.S., Misner J.W., Tustin J.M. Synthesis of 2-deoxy-2',2'difluoro-D-ribose and 2-deoxy-2',2'difluoro-D-ribofuranosyl nucleosides. J. Org. Chem. 1988, 53:2406-2409.
9. Hertel L.W., Boder G.B., Kroin J.S., Rinzel S.M., Poore G.A., Todd G.C., Grindey G.B. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res. 1990, 50:4417-4422.
10. Huang P., Plunkett W. Induction of apoptosis by gemcitabine. Semin. Oncol. 1995, 22:19-25.
11. Huang P., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991, 51:6110-6117.
12. Huang J., Robertson J.M., Ye H., Margolis J., Nadeau L., Yan D. Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2011, 10.1016/j.ijrobp.2011.09.022.
13. Iwata K., Aizawa K., Sakai S., Jingami S., Fukunaga E., Yoshida M., Hamada A., Saito H. The relationship between treatment time of gemcitabine and development of hematologic toxicity in cancer patients. Biol. Pharm. Bull. 2011, 34:1765-1768.
14. Kim T.H., Youn Y.S., Jiang H.H., Lee S., Chen X., Lee K.C. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogs: pharmacokinetics and anti-tumor effects. Bioconjug. Chem. 2011, 22:1631-1637.
15. Kroep J., van Moorsel C., Veerman G., Voorn D., Schultz R., Worzalla J., Tanzer L., Merriman R., Pinedo H., Peters G. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC). Adv. Exp. Med. Biol. 1998, 431:657-660.
16. Matsumoto K., Miyake Y., Kato H., Kawamoto H., Imagawa A., Toyokawa T., Nakatsu M., Ando M., Hirohata M., Yamamoto K. Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. Digestion 2011, 84:230-235.
17. Pollera C.F., Ceribelli A., Crecco M., Oliva C., Calabresi F. Prolonged infusion gemcitabine: a clinical phase I study at low- (300mg/m2) and high-dose (875mg/m2) levels. Invest. New Drugs 1997, 15:115-121.
18. Ruiz van Haperen V.W., Veerman G., Vermorken J.B., Peters G.J. 2', 2' -Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol. 1993, 46:762-766.
19. Sakamoto H., Kitano M., Suetomi Y., Takeyama Y., Ohyanagi H., Nakai T., Yasuda C., Kudo M. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J. Gastroenterol. 2006, 41:70-76.
20. Shipley L., Brown T., Cornpropst J., Hamilton M., Daniels W., Culp H. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab. Dispos. 1992, 20:849-855.
21. Tolis C., Peters G.J., Ferreira C.G., Pinedo H.M., Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur. J. Cancer 1999, 35:796-807.
22. Toschi L., Finocchiaro G., Bartolini S., Gioia V., Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncol. 2005, 1:7-17.
23. van der Wilt C.L., Kroep J.R., Bergman A.M., Loves W.J., Alvarez E., Talianidis I., Eriksson S., van Groeningen C.J., Pinedo H.M., Peters G.J. The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv. Exp. Med. Biol. 2000, 486:287-290.
24. Veltkamp S.A., Jansen R.S., Callies S., Pluim D., Visseren-Grul C.M., Rosing H., Kloeker-Rhoades S., Andre V.A., Beijnen J.H., Slapak C.A., Schellens J.H. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin. Cancer Res. 2008, 14:3477-3486.
25. Xue, X.X., Li, G., Sun, C.J., Li, W.B., 2009. Prodrugs based on gemcitabine structure as well as synthetic methods and the applications thereof. China Patent CN 101525361A.
26. Xue X., Qu X.J., Gao Z.H., Sun C.C., Liu H.P., Zhao C.R., Cheng Y.N., Lou H.X. Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II. Invest. New Drugs 2012, 30:212-222.
27. Zhao C.R., Xue X.X., Li G., Sun C.J., Sun C.C., Qu X.J., Li W.B. Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine. Chem. Biol. Drug Des. 2012, 10.1111/j.1747-0285.2012.01422.x.